Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + FOLFOX4 versus atezolizumab + bevacizumab for hepatocellular carcinoma with lung metastasis
ChiCTR2300071896Phase 3Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tretinoin, oxaliplatin, fluorouracil, folinic acid, atezolizumab and 1 more in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: overall survival. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
tretinoinoxaliplatinfluorouracilfolinic acidatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300071896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071896.